Benperidol

also known as Anquil · Benquil · MCN-JR-4584 · NSC-170982 · R-4584

Small molecule targets DRD2 via inhibition

today NCT02307396 · Ph 4 NCT02374567 · Ph 3

2015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 31 trial
Phase 3	NCT02374567	Jan 2015 → Jun 2017	anxiety disorder, dementia, depressive disorder, schizophrenia +1	Hannover Medical School	Terminated	No outcome recorded
Phase 41 trial
Phase 4	NCT02307396	Feb 2015 → Jun 2016	schizoaffective disorder, schizophrenia	Technical University of Munich	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT01323205 Background	May 2011 → Nov 2012	schizophrenia	Janssen Research & Development, LLC	Completed	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	Benperidol	“Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol...” NCT01323205 ↗ 2 NCT02374567 ↗ NCT02307396 ↗
Known as	Anquil	ChEMBL registry synonym — accepted as the source's own label CHEMBL297302 ↗
Known as	Benquil	ChEMBL registry synonym — accepted as the source's own label CHEMBL297302 ↗
Known as	MCN-JR-4584	ChEMBL registry synonym — accepted as the source's own label CHEMBL297302 ↗
Known as	NSC-170982	ChEMBL registry synonym — accepted as the source's own label CHEMBL297302 ↗
Known as	R-4584	ChEMBL registry synonym — accepted as the source's own label CHEMBL297302 ↗
Action	Inhibit	“Dopamine D2 receptor antagonist” CHEMBL297302 ↗
Modality	Small molecule	— CHEMBL297302 ↗
Target	DRD2	“Dopamine D2 receptor antagonist” CHEMBL297302 ↗